CEO Buys $11.92M in Stock; Company Grants $45M Equity Award to CEO and Announces Board Leadership Changes

summarizeSummary

Oscar Health's CEO made a significant personal stock purchase, while the company granted him a substantial new equity award and completed a major debt-to-equity conversion with a key investor, alongside board leadership changes.

check_boxKey Events

• CEO Makes Significant Personal Stock Purchase

  CEO Mark T. Bertolini purchased 1,000,000 Class A shares for $11.92 million at $11.92 per share on April 3, 2026, demonstrating strong confidence in the company's future.

• CEO Granted Substantial New Equity Award

  The company granted CEO Mark T. Bertolini new 2026 equity awards valued at $45 million, consisting of 50% time-based RSUs and 50% performance-based PSUs tied to relative Total Shareholder Return (TSR), aligning his incentives with long-term shareholder value.

• Major Debt-to-Equity Conversion Completed

  Dragoneer exchanged $250 million in 2031 Convertible Senior Notes for approximately 30 million Class A shares and an additional $17.8 million inducement payment (part cash, part shares), significantly altering the capital structure.

• Board Leadership Transition Announced

  The Board of Directors will be reduced to eight members, with current independent Chair Jeffery Boyd not standing for re-election. Siddhartha Sankaran has been designated as the new independent Board Chair.

auto_awesomeAnalysis

This definitive proxy statement reveals several material events. The most notable is CEO Mark T. Bertolini's $11.92 million open-market purchase of company stock, signaling strong insider conviction despite the company's reported $443.15 million net loss in 2025. Concurrently, the CEO was granted a substantial $45 million equity award for 2026, structured to align with long-term shareholder value through TSR performance. The company also completed a significant $250 million debt-to-equity conversion with Dragoneer, which included an inducement payment, impacting the capital structure. These events, alongside large new-hire compensation packages and board leadership changes, indicate active strategic and governance shifts at Oscar Health. Investors should monitor the impact of these compensation structures on future performance and the company's path to profitability.